BiotechTube

Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cataract

Conditions

Cataract

Trial Timeline

Sep 4, 2020 → Dec 21, 2023

NCT ID
NCT04539548

About Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%

Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1% is a phase 3 stage product being developed by Ocular Therapeutix for Cataract. The current trial status is completed. This product is registered under clinical trial identifier NCT04539548. Target conditions include Cataract.

What happened to similar drugs?

10 of 19 similar drugs in Cataract were approved

Approved (10) Terminated (3) Active (7)
✅Prednisolone acetateNovartisApproved
✅Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
✅Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
✅Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
✅Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04539548Phase 3Completed

Competing Products

20 competing products in Cataract

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
40
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
35
ISV-305Sun PharmaceuticalPhase 3
40
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
40
Prednisolone acetateNovartisApproved
43
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
24
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
37
Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
29
DexycuEyePoint PharmaceuticalsPhase 3
26
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
37
DexycuEyePoint PharmaceuticalsPhase 3
26
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
20
Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved
44
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
30
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
OMS302 + OMS302-PE + VehicleOmeros CorporationPhase 1/2
26